ALPRALID 1

Šalis: Izraelis

kalba: anglų

Šaltinis: Ministry of Health

Veiklioji medžiaga:

ALPRAZOLAM

Prieinama:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

ATC kodas:

N05BA12

Vaisto forma:

TABLETS

Sudėtis:

ALPRAZOLAM 1 MG

Vartojimo būdas:

PER OS

Recepto tipas:

Required

Pagaminta:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

Farmakoterapinė grupė:

ALPRAZOLAM

Gydymo sritis:

ALPRAZOLAM

Terapinės indikacijos:

Treatment of symptoms of tension and anxiety, anxiety accompanied by depression and in panic states with or without phobia.

Leidimo data:

2023-10-31

Pakuotės lapelis

PATIENT LEAFLET IN ACCORDANCE WITH
THE PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor's
prescription only
ALPRALID TABLETS 0.25, 0.5, 1 MG
ALPRALID 0.25: Each tablet contains:
Alprazolam 0.25 mg
ALPRALID 0.5: Each tablet contains:
Alprazolam 0.5 mg
ALPRALID 1: Each tablet contains:
Alprazolam 1 mg
Inactive ingredients and allergens in the
preparation - see section 6 “Additional
information” and the “Important information
about some ingredients of the medicine”
section.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE
USING THE MEDICINE. This leaflet contains
concise information about the medicine. If you
have any other questions, refer to the doctor
or the pharmacist.
This medicine has been prescribed for
treatment of your illness. Do not pass it on to
others. It may harm them even if it seems to
you that their medical condition is similar.
WHAT IS THE MOST IMPORTANT INFORMATION YOU
SHOULD KNOW ABOUT ALPRALID?
TAKING THIS MEDICINE TOGETHER WITH
OPIOID MEDICINES, WITH OTHER MEDICINES
THAT DEPRESS THE CENTRAL NERVOUS SYSTEM
(INCLUDING DRUGS) OR WITH ALCOHOL, MAY
CAUSE A SENSATION OF DEEP DROWSINESS,
BREATHING DIFFICULTIES (RESPIRATORY
DEPRESSION), COMA AND DEATH.
INTRODUCTION TO THE CONSUMER LEAFLET FOR
BENZODIAZEPINES
THIS MEDICINE BELONGS TO THE
BENZODIAZEPINES GROUP, WHICH HAS SPECIAL
CHARACTERISTICS THAT REQUIRE EXTRA CARE
DURING USE.
-
IT IS HIGHLY IMPORTANT TO BE UNDER CLOSE
MEDICAL SUPERVISION WHEN TAKING THIS
MEDICINE.
-
WHEN TAKING THIS MEDICINE, BE SURE TO
REFER TO THE DOCTOR AFTER 2-4 WEEKS, SINCE
THE TREATMENT IS ONLY INTENDED FOR SHORT
TIME PERIODS.
-
PROLONGED USE OF THIS MEDICINE MAY
CAUSE THE EFFECT OF THE MEDICINE TO
DECREASE. PROLONGED USE MAY CAUSE
SEVERE DEPENDENCY, MAKING IT DIFFICULT
FOR THE PATIENT TO STOP TAKING THE
MEDICINE.
-
UNCONTROLLED DISCONTINUATION OF THIS
TREATMENT WILL BE ACCOMPANIED BY
WITHDRAWAL EFFECTS, SUCH AS: STRESS,
NERVOUSNESS, CONFUSION, TREMOR,
INSOMNIA, ABDOMINAL PAIN, VOMITING,
NAUSEA, SWEATING, SPASMS, CRAMPS AND
MUSCLE PAIN.